Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1996 Jan;34(1):80–83. doi: 10.1128/jcm.34.1.80-83.1996

Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay.

J M Pawlotsky 1, A Bastie 1, C Pellet 1, J Remire 1, F Darthuy 1, L Wolfe 1, C Sayada 1, J Duval 1, D Dhumeaux 1
PMCID: PMC228735  PMID: 8748278

Abstract

Indeterminate hepatitis C virus (HCV) third-generation recombinant immunoblot assay (RIBA3.0; Ortho Diagnostic Systems) patterns were arbitrarily defined by the manufacturer as the detection of only one antibody out of the four that were sought, namely, c100 (NS4 encoded), c22 (core encoded), c33c (NS3 encoded), and NS5 (NS5 encoded). The aims of the present study were (i) to determine the prevalence of indeterminate RIBA3.0 patterns in patients consecutively tested for anti-HCV antibodies in a university hospital; (ii) to evaluate the significance of these patterns in terms of viral replication, liver disease, and risk factors for HCV; and (iii) to get an insight into the mechanism underlying this peculiar immune response. Among 3,074 serum samples consecutively tested for anti-HCV antibodies, 588 were found to be positive by screening assays. Fifty-nine of them (10%) were RIBA3.0 indeterminate and were compared with 59 RIBA3.0-positive ones. Thirty-one RIBA3.0-indeterminate and 53 RIBA3.0-positive serum samples were HCV RNA positive by PCR (53 versus 90%; P < 10(-6). RIBA3.0-indeterminate and RIBA-3.0-positive patients with positive PCR results were not significantly different for the prevalence of risk factors for HCV infection and elevated serum alanine aminotransferase activities. Immunosuppression, attributable to coexisting human immunodeficiency virus infection, organ transplantation, or the administration of immunosuppressive drugs, was significantly more frequent in PCR-positive, RIBA3.0-indeterminate patients than in PCR-negative, RIBA3.0 indeterminate patients (P < 0.001) and PCR-positive patients with a positive RIBA3.0 result (P < 0.01). The distribution of HCV genotypes did not differ significantly between HCV RNA-positive patients with indeterminate or positive RIBA3.0 results. In conclusion, the prevalence of indeterminate RIBA3.0 patterns in virology laboratories is about 10%; in about half of these patients HCV replication is detected by PCR; the main factor responsible for indeterminate RIBA3.0 patterns could be immunosuppression, whereas HCV genotypes do not seem to play major role.

Full Text

The Full Text of this article is available as a PDF (176.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bresters D., Zaaijer H. L., Cuypers H. T., Reesink H. W., Winkel I. N., van Exel-Oehlers P. J., van Drimmelen A. A., Jansen P. L., van der Poel C. L., Lelie P. N. Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non-A, non-B hepatitis patients. Transfusion. 1993 Aug;33(8):634–638. doi: 10.1046/j.1537-2995.1993.33893342743.x. [DOI] [PubMed] [Google Scholar]
  2. Buffet C., Charnaux N., Laurent-Puig P., Chopineau S., Quichon J. P., Briantais M. J., Dussaix E. Enhanced detection of antibodies to hepatitis C virus by use of a third-generation recombinant immunoblot assay. J Med Virol. 1994 Jul;43(3):259–261. doi: 10.1002/jmv.1890430312. [DOI] [PubMed] [Google Scholar]
  3. Chan T. M., Lok A. S., Cheng I. K., Chan R. T. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology. 1993 Mar;104(3):862–868. doi: 10.1016/0016-5085(93)91023-b. [DOI] [PubMed] [Google Scholar]
  4. Courouce A. M., Bouchardeau F., Girault A., Le Marrec N. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet. 1994 Apr 2;343(8901):853–854. [PubMed] [Google Scholar]
  5. Follett E. A., Dow B. C., McOmish F., Yap P. L., Hughes W., Mitchell R., Simmonds P. HCV confirmatory testing of blood donors. Lancet. 1991 Oct 19;338(8773):1024–1024. doi: 10.1016/0140-6736(91)91891-w. [DOI] [PubMed] [Google Scholar]
  6. Goffin E., Pirson Y., Cornu C., Jadoul M., van Ypersele de Strihou C. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet. 1994 Apr 2;343(8901):854–854. [PubMed] [Google Scholar]
  7. Halfon P., Rousseau S., Tamalet C., Antoni M., Gerolami V., Levy M., Bourliere M., Planells R., Cartouzou G. Indeterminate second-generation hepatitis C recombinant immunoblot test: detection of hepatitis C virus infection by polymerase chain reaction. J Infect Dis. 1992 Aug;166(2):449–449. doi: 10.1093/infdis/166.2.449. [DOI] [PubMed] [Google Scholar]
  8. Lau J. Y., Davis G. L., Brunson M. E., Qian K. P., Lin H. J., Quan S., DiNello R., Polito A. J., Scornik J. C. Hepatitis C virus infection in kidney transplant recipients. Hepatology. 1993 Nov;18(5):1027–1031. doi: 10.1016/0270-9139(93)90452-s. [DOI] [PubMed] [Google Scholar]
  9. Li X. M., Reddy K. R., Jeffers L. J., Parker T., de Medina M., Schiff E. R. Indeterminate hepatitis C. Lancet. 1993 Mar 27;341(8848):835–835. doi: 10.1016/0140-6736(93)90616-o. [DOI] [PubMed] [Google Scholar]
  10. Lok A. S., Chien D., Choo Q. L., Chan T. M., Chiu E. K., Cheng I. K., Houghton M., Kuo G. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology. 1993 Sep;18(3):497–502. [PubMed] [Google Scholar]
  11. Nolte F. S., Thurmond C., Fried M. W. Preclinical evaluation of AMPLICOR hepatitis C virus test for detection of hepatitis C virus RNA. J Clin Microbiol. 1995 Jul;33(7):1775–1778. doi: 10.1128/jcm.33.7.1775-1778.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pawlotsky J. M., Fleury A., Choukroun V., Deforges L., Roudot-Thoraval F., Aumont P., Duval J., Dhumeaux D. Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA. J Clin Microbiol. 1994 May;32(5):1357–1359. doi: 10.1128/jcm.32.5.1357-1359.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pawlotsky J. M., Maisonneuve P., Duval J., Dhumeaux D., Noel L. Significance of NS5-"indeterminate" third-generation anti-hepatitis C virus serologic assays. Transfusion. 1995 May;35(5):453–454. doi: 10.1046/j.1537-2995.1995.35595259159.x. [DOI] [PubMed] [Google Scholar]
  14. Pawlotsky J. M., Roudot-Thoraval F., Pellet C., Aumont P., Darthuy F., Remire J., Duval J., Dhumeaux D. Influence of hepatitis C virus (HCV) genotypes on HCV recombinant immunoblot assay patterns. J Clin Microbiol. 1995 May;33(5):1357–1359. doi: 10.1128/jcm.33.5.1357-1359.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pawlotsky J. M., Tsakiris L., Roudot-Thoraval F., Pellet C., Stuyver L., Duval J., Dhumeaux D. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis. 1995 Jun;171(6):1607–1610. doi: 10.1093/infdis/171.6.1607. [DOI] [PubMed] [Google Scholar]
  16. Ragni M. V., Ndimbie O. K., Rice E. O., Bontempo F. A., Nedjar S. The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV "seroreversion". Blood. 1993 Aug 1;82(3):1010–1015. [PubMed] [Google Scholar]
  17. Sayers M. H., Gretch D. R. Recombinant immunoblot and polymerase chain reaction testing in volunteer whole blood donors screened by a multi-antigen assay for hepatitis C virus antibodies. Transfusion. 1993 Oct;33(10):809–813. doi: 10.1046/j.1537-2995.1993.331094054616.x. [DOI] [PubMed] [Google Scholar]
  18. Stuyver L., Rossau R., Wyseur A., Duhamel M., Vanderborght B., Van Heuverswyn H., Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol. 1993 Jun;74(Pt 6):1093–1102. doi: 10.1099/0022-1317-74-6-1093. [DOI] [PubMed] [Google Scholar]
  19. Vernelen K., Claeys H., Verhaert H., Volckaerts A., Vermylen C. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet. 1994 Apr 2;343(8901):853–853. doi: 10.1016/s0140-6736(94)92054-0. [DOI] [PubMed] [Google Scholar]
  20. Young K. K., Resnick R. M., Myers T. W. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol. 1993 Apr;31(4):882–886. doi: 10.1128/jcm.31.4.882-886.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Zeuzem S., Rüster B., Roth W. K. Clinical evaluation of a new polymerase chain reaction assay (Amplicor HCV) for detection of hepatitis C virus. Z Gastroenterol. 1994 Jun;32(6):342–347. [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES